Stepan Company
NYSE:SCLChemicals - Specialty
+$0.46 today
- Market cap
- $1.50B
- Beta
- 0.97
- P/E (TTM)
- -87.3
- EPS (TTM)
- -$0.62
- Dividend yield
- 2.89%
Volume 0.13M
Average 0.15M
SCL Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Stepan CompanyNYSE: SCL
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $14.99M rose 2.3% year over year, behind the +6.3% change in trailing-twelve-month research & development. Sequentially, it fell 4.5% from the prior quarter. Over 3 fiscal years it compounded at -3.8% a year.
Context
- Research & development amounted to 2.5% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +2.3% toward the trailing-twelve-month pace of +6.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 59.28M USD
- Year-over-year change
- +6.5%
- 4-year CAGR
- -1.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 59.28M | +6.5% |
| FY2024 | 2024-12-31 | 55.67M | -5.7% |
| FY2023 | 2023-12-31 | 59.04M | -11.4% |
| FY2022 | 2022-12-31 | 66.63M | +6.3% |
| FY2021 | 2021-12-31 | 62.69M | — |
Research & Development vs competitors
How SCL compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +6.3% is the 2nd highest of 4, against a peer median of -9.9%.
- Research & development amounts to 2.5% of revenue for SCL, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | R$436M BRL | -9.9% | +6.4% | 0.7% | |
| LTM Mar 2026 | $59.62M USD | +6.3% | -3.8% | 2.5% | |
| LTM Mar 2026 | $16.09M USD | +261.3% | +113.3% | 59.8% | |
| LTM Apr 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Apr 2026 | $0 USD | — | +4.5% | 0.0% | |
| LTM Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding SCL) | — | -9.9% | +6.4% | 0.0% | |
Competitors are the stored peer set for SCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.35B | 2.77B | 2.33B | 2.18B | 2.33B |
| Cost of Revenue | 1.95B | 2.35B | 2.05B | 1.91B | 2.06B |
| Gross Profit | 395.81M | 427.07M | 277.6M | 272.21M | 269.89M |
| Gross Margin | 16.9% | 15.4% | 11.9% | 12.5% | 11.6% |
| Research & Development | 62.69M | 66.63M | 59.04M | 55.67M | 59.28M |
| Selling, General & Admin | 152.09M | 161.21M | 141.57M | 143.91M | 139.56M |
| Operating Expenses | 225.03M | 219.73M | 218.99M | 201.73M | 200.51M |
| Depreciation & Amortization | 90.88M | 94.65M | 105.34M | 112.2M | 126.04M |
| EBITDA | 270.42M | 294.24M | 169.68M | 192.1M | 212.17M |
| EBITDA Margin | 11.5% | 10.6% | 7.3% | 8.8% | 9.1% |
| Operating Income | 170.78M | 207.34M | 58.61M | 70.48M | 69.38M |
| Operating Margin | 7.3% | 7.5% | 2.5% | 3.2% | 3.0% |
| Interest Income | 1.26M | 1.08M | 3.84M | 5.28M | 4.11M |
| Interest Expense | 7.01M | 10.89M | 15.95M | 19.47M | 26.23M |
| Other Income / Expenses | 1.76M | (18.63M) | (10.22M) | (10.04M) | (9.48M) |
| Income Before Tax | 172.54M | 188.7M | 48.39M | 60.44M | 59.9M |
| Pre-Tax Margin | 7.4% | 6.8% | 2.1% | 2.8% | 2.6% |
| Income Tax Expense | 34.64M | 41.55M | 8.19M | 10.07M | 13.01M |
| Net Income | 137.8M | 147.15M | 40.2M | 50.37M | 46.9M |
| Net Margin | 5.9% | 5.3% | 1.7% | 2.3% | 2.0% |
| EPS (Basic) | 6.01 | 6.46 | 1.77 | 2.21 | 2.05 |
| EPS (Diluted) | 5.92 | 6.38 | 1.75 | 2.20 | 2.05 |
| Weighted Avg Shares | 22.92M | 22.78M | 22.78M | 22.9M | 22.87M |
| Weighted Avg Shares (Diluted) | 23.29M | 23.06M | 22.95M | 22.93M | 22.89M |
Stepan Company
NYSE:SCL
Intrinsic Alpha fair value
Locked
Current Price
$66.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.